Our client is preparing to launch into the crowded immunology sector where next-gen products with comparable clinical profiles need to compete against entrenched blockbusters, such as Abbvie’s Humira, as well as significantly discounted biosimilars. Within this context, a robust non-clinical differentiation strategy is key to demonstrate differentiated value to payers and secure coverage at an economically viable price.
Eradigm mapped each competitor’s support program offering and conducted in-depth interviews with the programs’ curators to pinpoint which support services provide the most value across key customers. This enables us to curate a bespoke best-in-class support services model, with tactical recommendations as to how these services should be executed.
